Ricardo D. Parrondo, MD

home / authors / ricardo-d-parrondo-md

Articles

$Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study$

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study

July 9th 2024

BGB-16673-101 (NCT05006716) is a phase 1 study of a bruton tyrosine kinase degrader (BGB-16673) in patients with relapsed or refractory CLL/SLL.

Dr Parrondo on the Use of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

Ricardo D. Parrondo, MD

March 28th 2024

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Dr Parrondo on the RedirecTT-1 Trial of Teclistamab Plus Talquetamab in Multiple Myeloma

Ricardo D. Parrondo, MD

February 14th 2024

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Dr Parrondo on the Investigation of GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma

Ricardo D. Parrondo, MD

February 7th 2024

Ricardo D. Parrondo, MD, discusses the exploration of the non-BCMA CAR T-cell target GPRC5D in multiple myeloma.

Dr Parrondo on the Current Treatment Landscape of MCL

Ricardo D. Parrondo, MD

October 23rd 2023

Ricardo D. Parrondo, MD, discusses the current treatment landscape of mantle cell lymphoma and highlights ongoing areas of investigation in other hematologic malignancies.

Dr Parrondo on the Clinical Benefit of Momelotinib on Anemia in Myelofibrosis

Ricardo D. Parrondo, MD

October 6th 2023

Ricardo D. Parrondo, MD, discusses the clinical benefit seen with momelotinib in anemic myelofibrosis, and where it fits into the current treatment paradigm in this disease landscape.